I agree 100% I can easily see them doing a revi

I agree 100%

I can easily see them doing a revised emergency IND, that would allow for very much broadened enrollment.

I also could definitely see banks wanting to be the one that did the lending to CytoDyn for the ramp up and product.

I think if and when this is found to decrease morbidity in a high percentage of patients, then we would see a couple things happen.

I think we would see Samsung step up production big time, the previous manufacturer would scale up production, and also possibly Samsung would work with one of their competitors to have them scale up production.

I think Federal Agencies would guarantee the payments for the product, and an agreed upon bank would provide a favorable financing package.

I also think Federal Agencies would work with transportation companies to mobilize this to the much needed areas.

Of course if leronlimab is a viable treatment that reduces morbidity, I think all of those things I listed are common sense. I would at least hope, anyway.